Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
Parekh S, Ratnani P, Falagario U, Lundon D, Kewlani D, Nasri J, Dovey Z, Stroumbakis D, Ranti D, Grauer R, Sobotka S, Pedraza A, Wagaskar V, Mistry L, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Martini A, Picker W, Haug E, Cormio L, Nordström T, Briganti A, Boström PJ, Carrieri G, Haines K, Gorin MA, Wiklund P, Menon M, Tewari A. Parekh S, et al. Among authors: perez im. Eur Urol Open Sci. 2022 May 20;41:45-54. doi: 10.1016/j.euros.2022.04.017. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813258 Free PMC article.
Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
Alinezhad S, Väänänen RM, Tallgrén T, Perez IM, Jambor I, Aronen H, Kähkönen E, Ettala O, Syvänen K, Nees M, Kallajoki M, Taimen P, Boström PJ, Pettersson K. Alinezhad S, et al. Among authors: perez im. Urol Oncol. 2016 Jun;34(6):255.e15-22. doi: 10.1016/j.urolonc.2015.12.014. Epub 2016 Feb 5. Urol Oncol. 2016. PMID: 26857646 Clinical Trial.
Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).
Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ. Jambor I, et al. Among authors: perez im. J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. doi: 10.1002/jmri.25641. Epub 2017 Feb 6. J Magn Reson Imaging. 2017. PMID: 28165653
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).
Jambor I, Kuisma A, Kähkönen E, Kemppainen J, Merisaari H, Eskola O, Teuho J, Perez IM, Pesola M, Aronen HJ, Boström PJ, Taimen P, Minn H. Jambor I, et al. Among authors: perez im. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):355-364. doi: 10.1007/s00259-017-3875-1. Epub 2017 Nov 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29147764 Clinical Trial.
Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.
Saarinen I, Jambor I, Kim M, Kuisma A, Kemppainen J, Merisaari H, Eskola O, Koskenniemi AR, Perez IM, Boström P, Taimen P, Minn H. Saarinen I, et al. Among authors: perez im. EJNMMI Res. 2019 May 31;9(1):50. doi: 10.1186/s13550-019-0518-5. EJNMMI Res. 2019. PMID: 31152256 Free PMC article.
Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study.
Salminen AP, Koskinen I, Perez IM, Hurme S, Murtola TJ, Vaarala MH, Nykopp TK, Seppänen M, Isotalo T, Marttila T, Levomäki L, Becker S, Anttinen M, Liukkonen T, Säily M, Pogodin-Hannolainen D, Viitanen J, Palmberg C, Ottelin J, Sairanen J, Ettala OO, Boström PJ. Salminen AP, et al. Among authors: perez im. Eur Urol Oncol. 2018 Dec;1(6):525-530. doi: 10.1016/j.euo.2018.06.014. Epub 2018 Jul 14. Eur Urol Oncol. 2018. PMID: 31158099
Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.
Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ. Jambor I, et al. Among authors: perez im. PLoS Med. 2019 Jun 3;16(6):e1002813. doi: 10.1371/journal.pmed.1002813. eCollection 2019 Jun. PLoS Med. 2019. PMID: 31158230 Free PMC article. Clinical Trial.
Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study.
Knaapila J, Jambor I, Perez IM, Ettala O, Taimen P, Verho J, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Knaapila J, et al. Among authors: perez im. Eur Urol Oncol. 2020 Oct;3(5):648-656. doi: 10.1016/j.euo.2019.08.008. Epub 2019 Sep 6. Eur Urol Oncol. 2020. PMID: 31501082
Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score.
Jambor I, Falagario U, Ratnani P, Perez IM, Demir K, Merisaari H, Sobotka S, Haines GK, Martini A, Beksac AT, Lewis S, Pahikkala T, Wiklund P, Nair S, Tewari A. Jambor I, et al. Among authors: perez im. J Magn Reson Imaging. 2020 Apr;51(4):1075-1085. doi: 10.1002/jmri.26928. Epub 2019 Sep 30. J Magn Reson Imaging. 2020. PMID: 31566845
24 results